WO2001068654A3 - Tubulin binding ligands and corresponding prodrug constructs - Google Patents

Tubulin binding ligands and corresponding prodrug constructs Download PDF

Info

Publication number
WO2001068654A3
WO2001068654A3 PCT/US2001/007539 US0107539W WO0168654A3 WO 2001068654 A3 WO2001068654 A3 WO 2001068654A3 US 0107539 W US0107539 W US 0107539W WO 0168654 A3 WO0168654 A3 WO 0168654A3
Authority
WO
WIPO (PCT)
Prior art keywords
binding ligands
tubulin binding
tubulin
aryl
ligands
Prior art date
Application number
PCT/US2001/007539
Other languages
French (fr)
Other versions
WO2001068654A2 (en
Inventor
Kevin G Pinney
Vani P Mocharla
Zhi Chen
Charles M Garner
Anjak Ghatak
Mallinath Hadimani
Jimmy Kessler
James M Dorsey
Original Assignee
Univ Baylor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Baylor filed Critical Univ Baylor
Priority to AU4352701A priority Critical patent/AU4352701A/en
Priority to DE60129536T priority patent/DE60129536T2/en
Priority to EP01916509A priority patent/EP1263763B1/en
Priority to AU2001243527A priority patent/AU2001243527B9/en
Priority to CA2407967A priority patent/CA2407967C/en
Priority to JP2001567745A priority patent/JP2004505888A/en
Publication of WO2001068654A2 publication Critical patent/WO2001068654A2/en
Publication of WO2001068654A3 publication Critical patent/WO2001068654A3/en
Priority to AU2006235967A priority patent/AU2006235967A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms
    • C07F9/655345Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms the sulfur atom being part of a five-membered ring
    • C07F9/655354Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms the sulfur atom being part of a five-membered ring condensed with carbocyclic rings or carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/45Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by at least one doubly—bound oxygen atom, not being part of a —CHO group
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/78Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C217/80Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings
    • C07C217/82Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring
    • C07C217/84Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring the oxygen atom of at least one of the etherified hydroxy groups being further bound to an acyclic carbon atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/78Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C217/94Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings being part of condensed ring systems and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/22Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00Ethers; Compounds having groups, groups or groups
    • C07C43/02Ethers
    • C07C43/20Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/215Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring having unsaturation outside the six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00Ethers; Compounds having groups, groups or groups
    • C07C43/02Ethers
    • C07C43/20Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/23Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/51Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by pyrolysis, rearrangement or decomposition
    • C07C45/511Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by pyrolysis, rearrangement or decomposition involving transformation of singly bound oxygen functional groups to >C = O groups
    • C07C45/512Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by pyrolysis, rearrangement or decomposition involving transformation of singly bound oxygen functional groups to >C = O groups the singly bound functional group being a free hydroxyl group
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/64Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by introduction of functional groups containing oxygen only in singly bound form
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/84Ketones containing a keto group bound to a six-membered aromatic ring containing ether groups, groups, groups, or groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/81Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/56Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/64Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/08Esters of oxyacids of phosphorus
    • C07F9/09Esters of phosphoric acids
    • C07F9/12Esters of phosphoric acids with hydroxyaryl compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/16Esters of thiophosphoric acids or thiophosphorous acids
    • C07F9/165Esters of thiophosphoric acids
    • C07F9/18Esters of thiophosphoric acids with hydroxyaryl compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/22Amides of acids of phosphorus
    • C07F9/24Esteramides
    • C07F9/2454Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/247Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic of aromatic amines (N-C aromatic linkage)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • C07F9/65517Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring condensed with carbocyclic rings or carbocyclic ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Abstract

A diverse set of tubulin binding ligands have been discovered which are structural by characterized, in a general sense, by a semi-rigid molecular framework capable of maintaining aryl-aryl, pseudo pi stacking distances appropriate for molecular recognition of tubulin. In phenolic or amino form, these ligands may be further functionalized to prepare phosphate esters, phosphate salts, and phosphoramides capable of demonstrating selective targeting and destruction of tumor cell vasculature.
PCT/US2001/007539 2000-03-10 2001-03-09 Tubulin binding ligands and corresponding prodrug constructs WO2001068654A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU4352701A AU4352701A (en) 2000-03-10 2001-03-09 Tubulin binding ligands and corresponding prodrug constructs
DE60129536T DE60129536T2 (en) 2000-03-10 2001-03-09 TUBULIN BINDING LIGANDS
EP01916509A EP1263763B1 (en) 2000-03-10 2001-03-09 Tubulin binding ligands
AU2001243527A AU2001243527B9 (en) 2000-03-10 2001-03-09 Tubulin binding ligands and corresponding prodrug constructs
CA2407967A CA2407967C (en) 2000-03-10 2001-03-09 Tubulin binding ligands and corresponding prodrug constructs
JP2001567745A JP2004505888A (en) 2000-03-10 2001-03-09 Tubulin binding ligands and corresponding prodrug structures
AU2006235967A AU2006235967A1 (en) 2000-03-10 2006-11-10 Tubulin binding ligands and corresponding prodrug constructs

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18829500P 2000-03-10 2000-03-10
US60/188,295 2000-03-10

Publications (2)

Publication Number Publication Date
WO2001068654A2 WO2001068654A2 (en) 2001-09-20
WO2001068654A3 true WO2001068654A3 (en) 2002-02-28

Family

ID=22692568

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/007539 WO2001068654A2 (en) 2000-03-10 2001-03-09 Tubulin binding ligands and corresponding prodrug constructs

Country Status (8)

Country Link
US (1) US6593374B2 (en)
EP (1) EP1263763B1 (en)
JP (1) JP2004505888A (en)
AT (1) ATE368046T1 (en)
AU (3) AU2001243527B9 (en)
CA (1) CA2407967C (en)
DE (1) DE60129536T2 (en)
WO (1) WO2001068654A2 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7001926B2 (en) 2000-03-10 2006-02-21 Oxigene, Inc. Tubulin binding agents and corresponding prodrug constructs
US7091240B2 (en) 2000-03-10 2006-08-15 Oxigene, Inc. Tubulin binding ligands and corresponding prodrug constructs
AUPR283801A0 (en) * 2001-02-01 2001-03-01 Australian National University, The Chemical compounds and methods
US7528165B2 (en) 2001-12-13 2009-05-05 National Health Research Institutes Indole compounds
US6933316B2 (en) 2001-12-13 2005-08-23 National Health Research Institutes Indole compounds
US7632955B2 (en) 2001-12-13 2009-12-15 National Health Research Institutes Indole compounds
US7456214B2 (en) 2004-05-03 2008-11-25 Baylor University Chromene-containing compounds with anti-tubulin and vascular targeting activity
US20050245489A1 (en) * 2004-05-03 2005-11-03 Pinney Kevin G Chromene-containing compounds with anti-tubulin and vascular targeting activity
SG169238A1 (en) * 2004-08-11 2011-03-30 Williamsburg Holdings Llc Noncardiotoxic pharmaceutical compounds
MX2007006102A (en) * 2004-11-22 2007-07-11 Threshold Pharmaceuticals Inc Tubulin binding anti cancer agents and prodrugs thereof.
US20060148674A1 (en) * 2004-12-31 2006-07-06 Luduena Richard F Therapeutic composition
US7456289B2 (en) * 2004-12-31 2008-11-25 National Health Research Institutes Anti-tumor compounds
KR101364762B1 (en) 2005-02-17 2014-02-17 신타 파마슈티칼스 코프. Compounds for the treatment of proliferative disorders
US7265248B1 (en) 2005-04-29 2007-09-04 Technology Innovations, Llc Compositions and methods for the treatment of malaria
CA2611712C (en) 2005-06-14 2014-05-13 Baylor University Combretastatin analogs with tubulin binding activity
NZ570014A (en) 2006-02-03 2011-04-29 Bionomics Ltd Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors
WO2009038731A2 (en) * 2007-09-17 2009-03-26 The Trustees Of Columbia University In The City Of New York Synthesis of resveratrol-based natural products
AU2008326251B2 (en) * 2007-11-21 2014-03-06 Mateon Therapeutics, Inc. Method for treating hematopoietic neoplasms
WO2011022772A1 (en) 2009-08-27 2011-03-03 Bionomics Limited Combination therapy for treating proliferative diseases
CA2771807A1 (en) 2009-08-27 2011-03-03 Bionomics Limited Treatment of macular degeneration
WO2014089177A2 (en) 2012-12-04 2014-06-12 Massachusetts Institute Of Technology Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
AU2014228822A1 (en) 2013-03-15 2015-10-01 Memorial Sloan-Kettering Cancer Center HSP90-targeted cardiac imaging and therapy
JP2018523712A (en) 2015-08-18 2018-08-23 マテオン セラピューティクス, インク.Mateon Therapeutics, Inc. Use of VDAS to improve immunomodulatory therapy against tumors
WO2017066668A1 (en) * 2015-10-15 2017-04-20 Baylor University Drug-linker conjugate pharmaceutical compositions
US10512631B2 (en) * 2015-10-23 2019-12-24 Beth Israel Deaconess Medical Center, Inc. Chalcone compounds
WO2017197045A1 (en) 2016-05-11 2017-11-16 Movassaghi Mohammad Convergent and enantioselective total synthesis of communesin analogs
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
WO2020247054A1 (en) 2019-06-05 2020-12-10 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998039323A1 (en) * 1997-03-06 1998-09-11 Baylor University Anti-mitotic agents which inhibit tubulin polymerization
WO2000048606A1 (en) * 1999-02-18 2000-08-24 Oxigene, Inc. Compositions and methods for use in targeting vascular destruction

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2401322A1 (en) 1977-08-22 1979-03-23 Thore Bernard IMPROVEMENTS TO ENGINE SYSTEMS INCLUDING A SUPERCHARGED INTERNAL COMBUSTION ENGINE
CA1338645C (en) * 1987-01-06 1996-10-15 George R. Pettit Isolation, structural elucidation and synthesis of novel antineoplastic substances denominated "combretastatins"
US4996237A (en) * 1987-01-06 1991-02-26 Arizona Board Of Regents Combretastatin A-4
JP2963288B2 (en) 1992-01-14 1999-10-18 株式会社海洋バイオテクノロジー研究所 Water-based harmful organism control agent
US5731353A (en) 1993-09-08 1998-03-24 Ajinomoto Co., Inc. Stilbene derivatives and pharmaceutical compositions containing them
TW325458B (en) 1993-09-08 1998-01-21 Ajinomoto Kk Stilbene derivatives and pharmaceutical compositions comprising the same for anti-cancer
US5596106A (en) 1994-07-15 1997-01-21 Eli Lilly And Company Cannabinoid receptor antagonists
US5561122A (en) * 1994-12-22 1996-10-01 Arizona Board Of Regents Acting On Behalf Of Arizona State University Combretastatin A-4 prodrug
ES2163587T3 (en) * 1995-02-28 2002-02-01 Lilly Co Eli BENZOTIOPHENE COMPOUNDS, INTERMEDIATE PRODUCTS, COMPOSITIONS AND PROCEDURES.
US5856340A (en) 1995-02-28 1999-01-05 Eli Lilly And Company Method of treating estrogen dependent cancers
TW334418B (en) 1995-03-07 1998-06-21 Ajinomoto Kk Stilbene derivatives and pharmaceutical compositions
US5596786A (en) * 1995-06-09 1997-01-28 Kluiters; Gam Triangular shaped floor mop
CA2214070C (en) 1996-08-29 2006-03-14 Eli Lilly And Company Dihydronaphthalene and naphthalene compounds, intermediates, formulations, and methods
RU2203890C2 (en) 1997-10-02 2003-05-10 Даиичи Фармасьютикл Компани, Лтд. Derivatives of dihydronaphthalene
GB9725953D0 (en) 1997-12-08 1998-02-04 Pfizer Ltd Compounds useful in therapy
US6162930A (en) * 1998-03-06 2000-12-19 Baylor University Anti-mitotic agents which inhibit tubulin polymerization
FR2777886B1 (en) * 1998-04-27 2002-05-31 Adir NOVEL BENZOTHIOPHENIC, BENZOFURANIC AND INDOLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US6110963A (en) 1998-05-12 2000-08-29 American Home Products Corporation Aryl-oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
US6166069A (en) 1998-05-12 2000-12-26 American Home Products Corporation Phenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
US6060488A (en) 1998-09-22 2000-05-09 Eli Lilly And Company Benzothiophenes for treating estrogen deficiency
NZ522074A (en) 2000-05-31 2004-06-25 Astrazeneca Ab Indole derivatives with vascular damaging activity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998039323A1 (en) * 1997-03-06 1998-09-11 Baylor University Anti-mitotic agents which inhibit tubulin polymerization
WO2000048606A1 (en) * 1999-02-18 2000-08-24 Oxigene, Inc. Compositions and methods for use in targeting vascular destruction

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FLYNN, BERNARD L. ET AL: "A novel palladium-mediated coupling approach to 2,3-disubstituted benzo[b]thiophenes and its application to the synthesis of tubulin binding agents", ORG. LETT. (2001), 3(5), 651-654, - 8 March 2001 (2001-03-08), XP002171975 *
PINNEY, KEVIN G. ET AL: "Synthesis of a benzo [b]thiophene-based vascular targeting prodrug and related anti-tubulin ligands.", ABSTR. PAP. - AM. CHEM. SOC. (2000), 220TH, ORGN-196, August 2000 (2000-08-01), XP001014188 *

Also Published As

Publication number Publication date
DE60129536T2 (en) 2008-06-19
CA2407967A1 (en) 2001-09-20
AU2001243527B2 (en) 2006-11-23
EP1263763B1 (en) 2007-07-25
US6593374B2 (en) 2003-07-15
DE60129536D1 (en) 2007-09-06
CA2407967C (en) 2010-10-05
EP1263763A2 (en) 2002-12-11
AU2001243527B9 (en) 2007-01-18
WO2001068654A2 (en) 2001-09-20
ATE368046T1 (en) 2007-08-15
AU4352701A (en) 2001-09-24
US20020055643A1 (en) 2002-05-09
AU2006235967A1 (en) 2006-11-30
JP2004505888A (en) 2004-02-26

Similar Documents

Publication Publication Date Title
WO2001068654A3 (en) Tubulin binding ligands and corresponding prodrug constructs
WO2004087061A3 (en) Tubulin binding agents and corresponding prodrug constructs
WO2003043631A3 (en) Method for identification of tumor targeting enzymes
WO2009100194A3 (en) Camptothecin-binding moiety conjugates
WO2003059251A3 (en) Antibody targeting compounds
WO2010040772A3 (en) Targeting construct comprising anti-polymer antibody and liposomes or microvesicles binding to the same
WO2006004833A3 (en) Pyrrolotriazine kinase inhibitors
WO2001072702A3 (en) Amidino compounds useful as nitric oxide synthase inhibitors
WO2007069068A3 (en) Cell penetrating peptide conjugates for delivering nucleic acids into cells
WO2003059378A3 (en) Combined use of a glp-1 compound and another drug for treating dyslipidemia
CY1114922T1 (en) Cytotoxic agents which include new tomomycin derivatives and their therapeutic use
WO2001070685A3 (en) Hydrazine-based and carbonyl-based bifunctional crosslinking reagents
EP2199338A3 (en) Polyetheralkanolamine dispersants
WO2009098510A3 (en) Nanoparticle conjugates
WO2008074487A3 (en) Lipids and lipid assemblies comprising transfection enhancer elements
WO2010020611A3 (en) Device for stacking bank notes
WO2002005782A3 (en) Stable salts of o-acetylsalicyclic with basic amino acids
WO2008103489A3 (en) Rna targeting compounds and methods for making and using same
WO2006078275A3 (en) Ionic liquid energetic materials
WO2005105154A8 (en) Polymer conjugate releasable under mild thiolytic conditions
WO2008068621A3 (en) Combination product with ido inhibitor and tumor targeted ifn-gamma
WO2008002460A3 (en) Orally available light-independent antineoplastic compounds
WO2001095884A3 (en) Liposomal benzoquinazoline thymidylate synthase inhibitor formulations
WO2004112717A3 (en) Conjugate for the specific targeting of anticancer agents to cancer cells and production thereof
WO2002077263A3 (en) Nucleic acid molecules encoding serine protease cvsp14, the encoded polypeptides and methods based thereon

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 567745

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2001243527

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2001916509

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2407967

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 2001916509

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2001916509

Country of ref document: EP